Mega Genomics Limited (HK:6667) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mega Genomics Limited reports a robust growth of 8.5% in revenue and a 5.3% increase in net profit for the first half of 2024, compared to the same period in 2023. Despite a significant 93.1% drop in cancer screening services, consumer genetic testing services surged by 83.2%. The company, a leader in China’s genetic testing market, has conducted over 21 million tests since its inception and is expanding its in-house developed product line.
For further insights into HK:6667 stock, check out TipRanks’ Stock Analysis page.